EMA Lapsed: Ontilyv (opicapone) — Bial Portela & Companhia S.A.

View source ↗

Summary

EMA has lapsed the marketing authorization for Ontilyv (opicapone) by Bial Portela & Companhia S.A. for Parkinson disease; the lapse is effective as of 11/07/20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Ontilyv (opicapone)

Snippet

Status: Lapsed. Therapeutic area: Parkinson Disease. MAH: Bial Portela & Companhia S.A.. Decision date: 11/07/2024